Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609787 | 0.91 | HDAC1 (0.53) | HDAC6HDAC1L3MBTL1LMNAMAPT | |
| SCHEMBL7606069 | 0.84 | HDAC6 (0.53) | HDAC6HDAC1 | |
| SCHEMBL7610043 | 0.83 | CCR2 (0.55) | HDAC6HDAC1LMNAMEN1KMT2A | |
| SCHEMBL7606181 | 0.83 | LRRK2 (0.55) | HDAC6HDAC1MEN1KMT2A | |
| SCHEMBL7652532 | 0.81 | PPARG (0.47) | HDAC6HDAC1L3MBTL1LMNAMAPT | |
| SCHEMBL7606183 | 0.75 | HDAC6 (0.43) | HDAC6HDAC1LMNAMEN1KMT2A | |
| SCHEMBL451443 | 0.74 | SENP5 (0.44) | HDAC6HDAC1LMNAMAPTPTGER4 | |
| SCHEMBL7612625 | 0.74 | SGMS2 (0.50) | HDAC6HDAC1LMNAMAPTMEN1 | |
| SCHEMBL7611336 | 0.73 | LRRK2 (0.55) | HDAC6HDAC1MEN1KMT2A | |
| SCHEMBL7607089 | 0.73 | LRRK2 (0.52) | HDAC6HDAC1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436965-B1 | INHIBITION OF PHOSPHODIESTERASE; 3-CARBOCYCLIC(ALKYL)OXY-2-ARYL(ALKYL)AMINOCARBONYL-1-ARYL(ALKYL)INDOLE OR AZAINDOLE DERIVATIVES | MERCK FROSST CANADA & CO. (CA) | 2002-08-20 | — | — | US | claimed |
| US-20020068756-A1 | PDE IV inhibiting amides, compositions and methods of treatment | MERCK FROSST CANADA LTD. (CA) | 2002-06-06 | — | — | US | claimed |
| US-6436965-B1 | INHIBITION OF PHOSPHODIESTERASE; 3-CARBOCYCLIC(ALKYL)OXY-2-ARYL(ALKYL)AMINOCARBONYL-1-ARYL(ALKYL)INDOLE OR AZAINDOLE DERIVATIVES | MERCK FROSST CANADA & CO. (CA) | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068756-A1 | PDE IV inhibiting amides, compositions and methods of treatment | PDE3A, PDE3B, PDE4A | HDAC6 59/4885HDAC1 45/4885L3MBTL1 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.